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Abstract
Background: Minocycline, a second-generation tetracycline antibiotic, has potential activity for the treatment of several
neurodegenerative and psychiatric disorders. However, its mechanisms of action remain to be determined.
Methodology/Principal Findings: We found that minocycline, but not tetracycline, significantly potentiated nerve growth
factor (NGF)-induced neurite outgrowth in PC12 cells, in a concentration dependent manner. Furthermore, we found that
the endoplasmic reticulum protein inositol 1,4,5-triphosphate (IP3) receptors and several common signaling molecules (PLC-
c, PI3K, Akt, p38 MAPK, c-Jun N-terminal kinase (JNK), mammalian target of rapamycin (mTOR), and Ras/Raf/ERK/MAPK
pathways) might be involved in the active mechanism of minocycline. Moreover, we found that a marked increase of the
eukaryotic translation initiation factor eIF4AI protein by minocycline, but not tetracycline, might be involved in the active
mechanism for NGF-induced neurite outgrowth.
Conclusions/Significance: These findings suggest that eIF4AI might play a role in the novel mechanism of minocycline.
Therefore, agents that can increase eIF4AI protein would be novel therapeutic drugs for certain neurodegenerative and
psychiatric diseases.
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Introduction
Accumulating evidence suggests that minocycline, a second-
generation tetracycline antibiotic, is a potential therapeutic drug
for several neurodegenerative and psychiatric disorders [1–5].
Minocycline is shown to have beneficial effects in animal models of
neurodegenerative disorders, including cerebral ischemia, amyo-
trophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s
disease, spinal cord injury, Alzheimer’s disease, and multiple
sclerosis [6–13]. Furthermore, minocycline is also reported to have
antipsychotic and neuroprotective effects in animal models of
schizophrenia and drug abuse [14–18]. A recent double-blind,
randomized study demonstrated that minocycline was effective in
the treatment of negative and cognitive symptoms of patients with
early-phase schizophrenia [19]. In addition, there is a case report
showing that minocycline was effective in the treatment of a
patient with methamphetamine-related disorders [20]. It is also
reported that minocycline reduced craving for cigarettes in
humans [21]. Interestingly, minocycline was effective in human
immunodeficiency virus (HIV) infection and reactivation as well as
HIV-induced neuronal damage, suggesting that this drug has
potential as an anti-HIV adjuvant therapy [22,23]. However, the
precise mechanisms underlying the beneficial effects of minocy-
cline are not fully understood.
The PC12 cell, a cell line from the rat pheochromocytoma of
the adrenal medulla, is a useful model for studying neurite
outgrowth [24,25]. The purpose of this study is to examine the
precise mechanisms underlying the beneficial effects of minocy-
cline. First, we examined the effects of minocycline and two other
tetracyclines (tetracycline, doxycycline) on nerve growth factor
(NGF)-induced neurite outgrowth in PC12 cells. In this study, we
found that minocycline, but not tetracycline, significantly poten-
tiated NGF-induced neurite outgrowth. Second, we examined the
precise cellular mechanisms underlying the potentiation by
minocycline of NGF-induced neurite outgrowth. Finally, we found
that eukaryotic translation initiation factor eIF4AI might be a
novel target for the potentiation of NGF-induced neurite
outgrowth by minocycline.
Results
Effects of three tetracyclines on NGF-induced neurite
outgrowth in PC12 cells
Minocycline (0.3, 1.0, 3.0, 10 or 30 mM) significantly increased
the number of cells with neurites induced by NGF (2.5 ng/ml), in
a concentration-dependent manner (Fig. 1). In contrast, tetracy-
cline (0.3, 1.0, 3.0, 10 or 30 mM) and doxycycline (0.3, 1.0, 3.0, or
10 mM) did not increase the number of cells with NGF (2.5 ng/
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cline (30 mM) significantly increased the number of cells with
neurites (Fig. 1). Immunocytochemistry using microtubule-associ-
ated protein 2 (MAP-2) antibody showed that minocycline
(30 mM), but not tetracycline (30 mM), increased the MAP-2
immunoreactivity in the cells with neurite (Fig. 2).
Figure 1. Effects of minocycline, tetracycline, or doxycycline on NGF-induced neurite outgrowth in PC12 cells. Minocycline, but not
tetracycline, significantly increased the number of cells with neurite, in a concentration-dependent manner. A high concentration (30 mM) of
doxycycline significantly increased the number of cells with neurite. Number is the concentration (mM) of drugs. ***P,0.001 as compared with
control (NGF (2.5 ng/ml) alone group). The data show the mean 6 SEM (n=8).
doi:10.1371/journal.pone.0015430.g001
Figure 2. Effects of minocycline and tetracycline on MAP-2 immunocytochemistry in PC12 cells. Representative photographs of MAP-2
immunocytochemistry in PC12 cells. (A) Control (NGF (2.5 ng/ml) alone) (B) NGF + minocycline (30 mM), (C) NGF + tetracycline (30 mM).
doi:10.1371/journal.pone.0015430.g002
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potentiation of NGF-induced neurite outgrowth by
minocycline
We examined the effects of the specific inhibitors of PLC-c,
PI3K, Akt, p38 MAPK, c-Jun N-terminal kinase (JNK) and
mammalian target of rapamycin (mTOR), since these signaling
molecules are activated upon the addition of NGF [24,26–28].
The PLC-c inhibitor (U73122; 1.0 mM), PI3K inhibitor
(LY294002; 10 mM), Akt inhibitor (1.0 mM), p38 MAPK inhibitor
(SB203580; 10 mM), JNK inhibitor (SP600125; 10 mM), and
mTOR inhibitor (rapamycin; 5.0 mM) significantly blocked the
potentiation of NGF-induced neurite outgrowth by minocycline
(30 mM) (Fig. 3). In contrast, these inhibitors alone did not alter
NGF-induced neurite outgrowth in PC12 cells (Fig. 3).
Role of the Ras/Raf/ERK/MAPK pathway in the
potentiation of NGF-induced neurite outgrowth by
minocycline
The Ras/Raf/ERK/MAPK pathway is known to be involved in
NGF-induced neurite outgrowth [24,26,27]. Therefore, we exam-
ined the effects of this pathway’s specific inhibitors. The Ras inhibitor
(GW5074; 1.0 mM), Raf inhibitor (lovastatin; 10 mM), MEK
inhibitor (U0126; 10 mM), MEK1/2 inhibitor (SL327; 10 mM), and
MAPK inhibitor (PD98059; 10 mM) significantly blocked the
potentiation of NGF-induced neurite outgrowth by minocycline
(30 mM) (Fig. 4). In contrast, U0124 (10 mM), an inactive analog of
U0126, did not alter the potentiation of NGF-induced neurite
outgrowth by minocycline. Furthermore, these inhibitors alone did
not alter NGF-induced neurite outgrowth in PC12 cells (Fig. 4).
Role of IP3 receptors in the potentiation of NGF-induced
neurite outgrowth by minocycline
Previously, we reported that receptors of the endoplasmic
reticulum (ER) protein inositol 1,4,5-triphosphate (IP3) play a role
in the potentiation of NGF-induced neurite outgrowth by the
antidepressant fluvoxamine [24] and anti-dementia drug donepe-
zil [25]. To investigate the role of IP3 receptors in minocycline’s
action on NGF-induced neurite outgrowth, we examined the
effects of xestospongin C (a selective, reversible, and membrane-
permeable inhibitor of IP3 receptors) [29] on the effects of
minocycline on NGF-induced neurite outgrowth. Co-administra-
tion of xestospongin C (1.0 mM) significantly blocked the
potentiation of NGF-induced neurite outgrowth by minocycline
(30 mM) (Fig. 5). Furthermore, administration of xestospongin C
(1.0 mM) alone did not alter NGF-induced neurite outgrowth in
PC12 cells (Fig. 5).
Lack of PARP-1 and 5-lipooxygenase in the potentiation
of NGF-induced neurite outgrowth by minocycline
It has been reported that minocycline is a potent inhibitor for
poly (ADP-ribose) polymerase-1 (PARP-1), which is involved in
neuroprotective actions [30]. To investigate the role of PARP-1,
we examined the effects of two established PARP-1 inhibitors,
DPQ [3,4-dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquino-
line] and PJ34 [N-(6-oxo-5, 6-dihydrophenanthridin-2-yl)-N,N-
dimethylacetamide hydrochloride], on the NGF-induced neurite
outgrowth in PC12 cells. Administration of DPQ (0.1, 1 and
10 mM) or PJ34 (0.1, 1 and 10 mM) did not alter the NGF-induced
neurite outgrowth (Fig. 6).
Figure 3. Effects of the specific inhibitors of PLC-c, PI3K, p38MAPK, JNK, and mTOR on potentiation of NGF-induced neurite
outgrowth by minocycline. The potentiating effects of minocycline (30 mM) on the NGF (2.5 ng/ml)-induced neurite outgrowth were antagonized
by co-administration of the PLC-c inhibitor (U73122; 1.0 mM), the PI3K inhibitor (LY294002; 10 mM), Akt inhibitor (1.0 mM), the p38MAPK inhibitor
(SB203580; 10 mM), the JNK inhibitor (SP600125; 10 mM), and mTOR inhibitor (rapamycin; 5.0 mM). ***P,0.001 as compared with control (NGF
(2.5 ng/ml) alone group). The data show the mean 6 SEM (n=6–18).
doi:10.1371/journal.pone.0015430.g003
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15430Figure 4. Effects of the specific inhibitors of Ras, Raf, MEK1/2, and MAPK on potentiation of NGF-induced neurite outgrowth by
minocycline. The potentiating effects of minocycline (30 mM) on the NGF-induced neurite outgrowth were antagonized by co-administration of the
Ras inhibitor (GW5074; 1.0 mM), the Raf inhibitor (lovastatin; 10 mM), the MEK inhibitor (U0126; 10 mM), the MEK1/2 inhibitor (SL327; 10 mM),and the
MAPK inhibitor (PD98059; 10 mM). In contrast, U0124 (10 mM), an inactive analog of U0126, did not alter the number of cells with neurite by
minocycline treatment. ***P,0.001 as compared with control (NGF (2.5 ng/ml) alone group). The data show the mean 6 SEM (n=6–14).
doi:10.1371/journal.pone.0015430.g004
Figure 5. Effects of the IP3 receptor antagonist on potentiation of NGF-induced neurite outgrowth by minocycline. The potentiating
effects of minocycline (30 mM) on the NGF-induced neurite outgrowth were antagonized by co-administration of the selective IP3 receptor antagonist
xestspongin C (1.0 mM). In contrast, xestspongin C (1.0 mM) alone did not alter NGF-induced neurite outgrowth. ***P,0.001 as compared with control
(NGF (2.5 ng/ml) alone group). The data show the mean 6 SEM (n=6–18).
doi:10.1371/journal.pone.0015430.g005
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N-methyl-D-aspartate (NMDA)-induced neuronal injury via
inhibiting 5-lipoxygenase activation, which is involved in the
neuroprotective actions [31]. To investigate the role of 5-
lipoxygenase, we examined the effects of MK-886, the established
inhibitor of 5-lipoxygenase-activation protein, on the potentiation
of NGF-induced neurite outgrowth by minocycline. Administra-
tion of MK-886 (0.01, 0.1, and 1 mM) did not alter the NGF-
induced neurite outgrowth in PC12 cells (Fig. 6). In contrast, a
high concentration of MK-886 (10 mM) significantly decreased the
number of PC12 cells with neurite outgrowth (Fig. 6), suggesting
that a high concentration (10 mM) of MK-886 may cause
cytotoxicity in PC12 cells.
Role of eIF4AI in the potentiation of NGF-induced neurite
outgrowth by minocycline
To determine the molecular target of minocycline’s action on
NGF-induced neurite outgrowth, we performed two-dimensional
gel electrophoresis proteome analysis. In PC12 cells, we found
increased levels of eukaryotic translation initiation factor eIF4AI
protein, an RNA-dependent ATPase and an ATP-dependent
helicase that unwinds the local secondary structure in mRNA to
allow binding of the 43S ribosomal complex [32–34], after
treatment with minocycline (30 mM) but not tetracycline (30 mM)
(Fig. S1).
To determine whether eIF4AI mediates the potentiation of
NGF-induced neurite outgrowth by minocycline, we treated PC12
cells with eIF4AI RNA interference (RNAi), which reduces the
expression of the eIF4AI protein. As shown in Fig. 7A, the increase
of the eIF4AI protein by minocycline (30 mM) was significantly
blocked by treatment with eIF4AI RNAi, but not by the negative
control of eIF4AI RNAi. In contrast, neither treatment with
eIF4AI RNAi nor that by the negative control of eIF4AI RNAi
altered the basal levels of eIF4AI protein (Fig. 7A). Furthermore,
the potentiating effects of minocycline on NGF-induced neurite
outgrowth were significantly antagonized by treatment with
eIF4AI RNAi, but not by the negative control of eIF4AI
(Fig. 7B). In contrast, neither treatment with eIF4AI RNAi nor
that with the negative control of eIF4AI RNAi altered the NGF-
induced neurite outgrowth in PC12 cells (Fig. 7B).
Discussion
The major findings of this study are that minocycline, but not
tetracycline, could potentiate NGF-induced neurite outgrowth in
PC12 cells, and that the IP3 receptors and several common cellular
signaling pathways might be involved in the mechanism of action
for potentiation of NGF-induced neurite outgrowth by minocy-
cline. Interestingly, we identified the eukaryotic initiation factor
eIF4AI as distinguishing different protein levels of minocycline and
tetracycline. This study suggests that increase in the eIF4AI
Figure 6. Effects of PARP-1 inhibitors and 5-lipoxygenase inhibitor on NGF-induced neurite outgrowth in PC12 cells. Administration
of PARP-1 inhibitors (DPQ or PJ34) or selective 5-lipoxygenase inhibitor MK-886 did not alter the NGF-induced neurite outgrowth in PC12 cells. The
data show the mean 6 SEM (n=6–18).
doi:10.1371/journal.pone.0015430.g006
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NGF-induced neurite outgrowth by this drug. Therefore, it is
likely that eIF4AI is a novel cellular target for minocycline’s action.
NGF binds to the high-affinity tyrosine receptor TrkA, initiating
several signaling pathways affecting both morphological and
transcriptional targets [24,26,27]. The signaling molecules,
including PLC-c, PI3K, Akt, p38 MAPK, and JNK, are activated
upon the addition of NGF [35]. PLC-c catalyzes the hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol
(DAG) and IP3. DAG activates protein kinase C, and IP3
promotes transient release of Ca
2+ from the ER via stimulation
at IP3 receptors. Thus, the pathway via PLC-c is responsible for
NGF-induced neurite outgrowth [24,36]. Furthermore, stimula-
tion of PI3K is reported to be involved in the promotion of neurite
outgrowth in PC12 cells [24,37]. In this study, we found that the
PLC-c inhibitor U73122, the PI3K inhibitor LY294002, the Akt
inhibitor, and the mTOR inhibitor rapamycin significantly
blocked the potentiation of NGF-induced neurite outgrowth by
minocycline. Moreover, we found that both the p38MAPK
inhibitor SB203580 and the JNK inhibitor SP600125 significantly
blocked the potentiation of NGF-induced neurite outgrowth by
minocycline. Additionally, we found that the specific inhibitors for
the Ras/Raf/MEK/MAPK pathways significantly blocked the
potentiation of NGF-induced neurite outgrowth by minocycline.
Taken together, these findings suggest that common signaling
pathways, including PLC-c, PI3K, Akt-mTOR, p38MAPK, the
JNK, and the Ras/Raf/MEK/MAPK, are involved in the
mechanisms of the potentiation of NGF-induced neurite out-
growth by minocycline. Considering the role of the PI3K/Akt/
mTOR pathway and the ERK/MAPK signaling pathway in the
control of protein synthesis-dependent learning and memory [38],
the present results may be of interest.
Several clinical studies showed that a single subanaesthetic dose
of the N-methyl-D-aspartate (NMDA) receptor antagonist keta-
mine caused a rapid antidepressant effect within hours of
administration in treatment-refractory patients with major depres-
sion [39,40]. Accumulating evidence suggests that the excitatory
amino acid glutamate plays a key role in the pathophysiology of
major depression although the precise mechanisms underlying
rapid-antidepressant effects of ketamine are unclear [41–43]. Very
recently, Li et al. [44] reported the role of the mTOR signaling
pathway in the rapid antidepressant effects of ketamine. Ketamine
rapidly activated the mTOR signaling pathway, leading to
increased synaptic signaling proteins and increased number and
function of new spines synapses in the rat prefrontal cortex.
Infusion of the mTOR inhibitor rapamycin into rat prefrontal
cortex prevented antidepressant-like effects of ketamine in several
animal models. Activation of mTOR signaling caused increased
levels of the phosphorylated and activated forms of eukaryotic
initiation factor 4E binding protein (4E-BP1). This paper suggests
that the rapid activation of mTOR signaling pathway may be an
important role in the mechanisms of rapid antidepressant effects of
the NMDA receptor antagonists [44] since PI3K/Akt/mTOR
signaling pathway are involved in the neurite outgrowth and the
control of protein synthesis-dependent learning and memory
[38,45,46]. Interestingly, there is a case reporting that minocycline
was effective in the treatment of depressive symptoms in a patient
with mood disorder [47], suggesting a possible antidepressant
effect of minocycline [48]. Taken together, it is likely that
minocycline might have antidepressant-activity since Akt/mTOR
Figure 7. Increase in eIF4AI protein is required for minocycline-induced potentiation of NGF-induced neurite outgrowth in PC12
cells. (A) The potentiating effects of minocycline (30 mM) on the eIF4AI protein levels were significantly antagonized by treatment of eIF4AI RNAi, but
not negative RNAi. In contrast, eIF4AI RNAi or negative RNAi alone did not alter the levels of eIF4AI protein in the control (NGF (2.5 ng/ml)-treated)
group. The data show the mean 6 SEM (n=8). ***p,0.001 as compared with minocycline (30 mM) group. (B) The potentiating effects of minocycline
(30 mM) on the NGF-induced neurite outgrowth were significantly antagonized by treatment of eIF4AI RNAi, but not negative RNAi. In contrast, eIF4AI
RNAi or negative RNAi alone did not alter NGF (2.5 ng/ml)-induced neurite outgrowth. The data show the mean 6 SEM (n=8). ***p,0.001 as
compared with minocycline (30 mM) group.
doi:10.1371/journal.pone.0015430.g007
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NGF-induced neurite outgrowth by this drug.
The intracellular Ca
2+ is an important regulator of neurite
outgrowth [49,50]. It has been reported that calcium signaling
mediated by IP3 receptors resulted in neurite outgrowth,
suggesting that IP3-mediated Ca
2+ release from internal stores is
necessary to maintain [Ca
2+]i, within the optimum range of
neurite outgrowth [51]. In the present study, we found that the IP3
receptor antagonist xestospongin C significantly blocked the
potentiation of NGF-induced neurite outgrowth by minocycline,
suggesting the role of IP3 receptors on the potentiation of NGF-
induced neurite outgrowth by minocycline. Previously, we
reported that IP3 receptors play a role in the potentiation of
NGF-induced neurite outgrowth by other drugs, including
fluvoxamine, donepezil, or ROCK inhibitor Y-27632 [24,25,52].
Taken together, it seems that the IP3 receptors on the ER play an
important role in the mechanism underlying the potentiation of
NGF-induced neurite outgrowth by minocycline.
Protein synthesis (or translation) in eukaryotic cells is funda-
mental for gene expression and is mainly regulated at the initiation
step. Translation initiation is a complex process that begins with
interaction of the cap-binding protein complex eukaryotic
initiation factor 4 (eIF4) families. First, eIF4E binds the cap
structure at the 59-untranslated region (UTR) of the mRNA. Next,
eIF4A, an ATPase/RNA helicase, unwinds the secondary
structure in the 59-UTR, allowing the small ribosomal subunit to
scan along the mRNA and to reach the start codon [34,53]. In the
present study, we found that an increase in the levels of eIF4AI
protein by minocycline might play a role in the mechanism of the
potentiation of NGF-induced neurite outgrowth by minocycline
although the precise mechanisms underlying the minocycline-
induced increase of eIF4AI are currently unclear. Very recently,
Fukao et al. [54] reported that the RNA-binding protein HuD can
induce neurite outgrowth in PC12 cells through direct interaction
with eIF4A in the 59 cap-binding complex, suggesting the
important role of eIF4A in neuronal outgrowth [54,55]. Taken
together, it is likely that eIF4A families including eIF4AI play a
role in neurite outgrowth, indicating that eIF4A may be a potential
target for developing therapeutic drugs for neurodegenerative and
psychiatric diseases. Therefore, agents that can increase the eIF4A
protein may have therapeutic relevance in diverse conditions with
altered neurite outgrowth.
Translation initiation factors have been implicated in the
pathophysiology of certain neuropsychiatric diseases because
translational control plays a role in neuronal plasticity [38,56]. It
is also suggested that dysregulation of the translational control
might play a part in cancer or the neurodegenerative disease
termed ‘‘vanishing white matter’’ [57,58]. Thus, it seems that
mutations or reduced expression of translation initiation factors
might be implicated in the pathophysiology of several diseases.
Considering the beneficial effects of minocycline in several animal
models, it is likely that eukaryotic translation initiation factors,
including eIF4AI, would be novel therapeutic targets for certain
neurodegenerative and psychiatric diseases.
Postmortem human brains are critical for examining molecular
changes associated with the pathophysiology of neuropsychiatric
diseases. At present, there are no reports showing alteration in
translation initiation factors eIF4AI in the postmortem brain
samples from patients with neuropsychiatric diseases. However,
there is a paper reporting that the strong expression of
phosphorylation of another translation initiation factor eIF2a
observed in subpopulations of neurons bearing neurofibrillary
tangles or pretangles in the postmortem brain from patients with
Alzheimer’s disease [59], suggesting that factors linked with tau
deposition might regulate protein synthesis throughout eIF2a
phosphorylation in certain neurons of Alzheimer’s disease.
Therefore, it may be interesting to examine whether expression
of eIF4AI is altered in the postmortem brain samples from
neuropsychiatric disease.
Recently, Bruno et al. [60] reported that, in a transgenic mouse
Alzheimer’s disease model, minocycline could diminish altered
matrix metalloproteinase 9, an enzyme of NGF degradation,
suggesting that minocycline may affect extracellular concentration
of NGF in the cell culture. Using a NGF immunoassay system, we
measured the levels of NGF in the cell culture medium in order to
examine whether minocycline can affect NGF concentration in the
medium of PC12 cells. However, we did not find any change of
NGF levels in the cell culture treated with vehicle or minocycline
(Fig. S2). Therefore, it is unlikely that minocycline alter the
stability/activity of added NGF in the PC12 cells.
In conclusion, the present results suggest that minocycline, but
not tetracycline, could potentiate NGF-induced neurite outgrowth
in PC12 cells, and that interaction with IP3 receptors and several
cellular signaling pathways are involved in the mechanism
underlying the pharmacological action of minocycline. Further-
more, we identified eIF4AI as a novel target for the mechanisms of
action of minocycline. Finally, these findings offer new approaches
for developing potential therapeutic drugs that can target
translation initiation factors including eIF4A.
Materials and Methods
Drugs
The drugs were obtained from the following sources: xestos-
pongin C, MK-886 (Wako Pure Chemicals Inc., Tokyo, Japan);
minocycline hydrochloride, doxycycline hydrochloride, tetracy-
cline hydrochloride, LY294002 (Sigma-Aldrich, St Louis, MO);
NGF (Promega, Madison, WI); lovastatin, PD98059, GW5074,
SB203580, MEK 1/2 inhibitor (SL327), SP600125, U0126,
U0124, DPQ, PJ34, rapamycin (Calbiochem-Novabiochem, San
Diego, CA), and Akt inhibitor (Bio Vision Inc., CA). Other drugs
were purchased from commercial sources.
Cell culture
PC12 sells (RIKEN Cell Bank, Tsukuba, Japan) were cultured
at 37uC, 5% CO2 with Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% heat-inactivated fetal bovine
serum (FBS), 10% heat-inactivated horse serum, and 1%
penicillin. The medium was changed two or three times a week.
PC12 cells were plated onto 24-well tissue culture plates coated
with poly-D-lysine/laminin. Cells were plated at relatively low
density (0.25610
4 cells/cm
2) in DMEM medium containing 0.5%
FBS, 1% penicillin streptomycin. Medium containing a minimal
level of serum (0.5% FBS) was used as previously reported [24,25].
Previously, we examined the optimal concentration of NGF for
NGF-induced neurite outgrowth in PC12 cells. NGF (2.5, 5, 10,
20, 40 ng/ml) increased the number of cells with neurite
outgrowth in PC12 cells, in a concentration-dependent manner
[24]. In the present studies, 2.5 ng/ml of NGF was used to study
the potentiating effects of tetracyclines on NGF-induced neurite
outgrowth. Twenty-four hours after plating, the medium was
replaced with DMEM medium containing 0.5% FBS and 1%
penicillin streptomycin with NGF (2.5 ng/ml) with or without
several drugs.
Quantification of neurite sprouting
Four days after incubation with NGF (2.5 ng/ml) with or
without the several drugs, morphometric analysis was performed
Minocycline and Translation Initiation Factor
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illumination with an inverted microscope linked to a camera.
Images of three fields per well were taken, with an average of 100
cells per field. Differentiated cells were counted by visual
examination of the field; only cells that had at least one neurite
with a length equal to the cell body diameter were counted, and
were then expressed as a percentage of the total cells in the field.
The counting was performed in a blinded manner.
MAP-2 immunocytochemistry in PC12 cells
Cells were fixed for 30 min at room temperature with 4%
paraformaldehyde then permeabilized with 0.2% Triton and
blocked with 1.5% normal goat serum, 0.1% bovine serum
albumin (BSA) in 0.1 M phosphate-buffer saline for 1 h to reduce
nonspecific binding. Cells were incubated overnight at 4uC with
anti-microtubule-associated protein 2 (MAP-2) antibodies (1:1000
dilution in blocking solution, Chemicon International, Temecula,
CA, USA). The immunolabeling was visualized with secondary
antibodies conjugated to Alexa-488 (1:1000; Invitrogen, Carlsbad,
CA, USA). MAP-2 immuncytochemistry was visualized with a
fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkocken,
Germany).
Western blot analysis
PC12 cells were washed with PBS and lysed in Laemmli lysis
buffer. Aliquots (30 mg) of the proteins were measured by DC
protein assay kit (Bio-Rad, Hercules, CA, USA) and incubated for
5 min at 95uC with an equal volume of 125 mM Tris/HCl,
pH 6.8, 20% glycerol, 0.1% bromphenol blue, 10% b-mercapto-
ethanol, 4% SDS, and subjected to SDS-PAGE using 7.5% mini-
gels (Mini ProteanII; Bio-Rad, Hercules, CA, USA). Proteins were
transferred onto PVDF membranes using a Trans Blot Mini Cell
(Bio-Rad, Hercules, CA, USA). For immunodetection, the blots
were blocked for 1 h in TBST (50 mM Tris/HCl, pH 7.8, 0.13 M
NaCl, 0.1% Tween 20) containing 5% nonfat dry milk at room
temperature (RT), followed by incubation with rabbit anti-eIF4AI
antibody (1:250, ab31217, Abcam, Cambridge, UK) overnight at
4uC in TBST/5% blocker. The blots were washed five times with
TBST. Incubation with the secondary antibody (GE Healthcare
Bioscience, UK) was performed for 1 h at RT. After extensive
washing, immunoreactivity was detected by ECL plus Western
Blotting Detection system (GE Healthcare Bioscience, UK).
Images were captured using a Fuji LAS3000-mini imaging system
(Fujifilm, Tokyo, Japan) with the Multi Gauge software (Ver.3.0;
Fujifilm, Tokyo, Japan) and immunoreactive bands were quanti-
fied. b-actin immunoreactivity was used to monitor equal sample
loading.
RNAi transfection
RNAi gene expression knockdown studies were performed using
the TriFECTa RNAi kit (Integrated DNA Technologies, Coralville,
CA) and corresponding protocol. Each 27 mer RNAi duplex was
transfected into cells using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) following the manufacturer’s guidelines. RNAi was
purchased from Integrated DNA Technologies (Coralville, CA).
The following sequences: Rattus norvegicus eukaryotic translation
initiation factor 4AI (Eif4aI), mRNA GenBank Accession
No. NM_199372 (RNC.RNAI.N199372.10.1; IDT): sense, 59-
GGAACGAGACGUGAUCAUGAGGGAG-39; antisense, 59-
CUCCCUCAUGAUCACGUCUCGUUCCUU-39 (RNC.RNAI.
N199372.10.2; IDT): sense, 59-CCUAAUCACCUCAUUCCU-
AAAGGCT-39; antisense, 59-AGCCUUUAGGAAUGAGGUGA-
UUAGGUU-39(RNC.RNAI.N199372.10.3; IDT): sense, 59-GC-
UGGACCAAAUCUACAGGGAGAAC-39; antisense, 59-GU-
UCUCCCUGUAGAUUUGGUCCAGCAA-39. For all relative
control experiments, cells were exposed to a scrambled non-specific
RNAi duplex with the following sequence: sense, 59-CUUCCU-
CUCUUUCUCUCCCUUGUGA-39; antisense, 59-UCACAAG-
GGAGAGAAAGAGAGGAAGGA-39.
Statistical analysis
Data are expressed as means 6 standard error of the mean
(SEM). Statistical analysis was performed by using one-way
analysis of variance (ANOVA) and the post hoc Bonferroni/Dunn
test. P values less than 0.05 were considered statistically significant.
Supporting Information
Figure S1 Effects of minocycline and tetracycline on
eIF4AI levels in PC12 cells PC12 cells were treated with
control (NGF (2.5 ng/ml)), minocycline (30 mM) or tetracycline
(30 mM) for 5 days. Then cells were washed with PBS, and lysed in
Laemmli lysis buffer. Western blot analysis was performed using
rabbit anti-eIF4AI antibody (1:250, ab31217, Abcam, Cambridge,
UK). The levels of eIF4AI protein in PC12 cells were significantly
increased by treatment with minocycline (30 mM), but not
tetracycline (30 mM). The data show the mean 6 SEM (n=8).
***p,0.001 as compared with control (NGF (2.5 ng/ml) alone)
group. (TIF)
Figure S2 Effects of minocycline on NGF levels in PC12
cells PC12 cells were treated with control (NGF (2.5 ng/ml)) or
minocycline (30 mM) for 5 days. The levels of NGF in the culture
medium were measured using NGF Emax Immunoassay system
(Promega, Madison, WI). The levels of NGF in the culture medium
of PC12 cells were not altered by treatment with minocycline
(30 mM). The data show the mean 6 SEM (n=6). (DOC)
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